Short Interest in Hypermarcas (OTCMKTS:HYPMY) Drops By 99.5%

Hypermarcas (OTCMKTS:HYPMY) saw a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 16 shares, a decrease of 99.5% from the May 14th total of 3,352 shares. Based on an average daily volume of 88,307 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy”.

Hypermarcas Stock Up 2.9%

HYPMY opened at $4.08 on Wednesday. Hypermarcas has a fifty-two week low of $3.71 and a fifty-two week high of $5.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.84 and a current ratio of 1.27. The company has a fifty day moving average of $4.52 and a two-hundred day moving average of $4.48. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of 8.49 and a beta of 0.70.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. The company had revenue of $383.13 million during the quarter. On average, research analysts expect that Hypermarcas will post 0.53 earnings per share for the current year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.